Distinguished in Primary Lymphoma of the Brain

Dr. Tatyana A. Feldman

Oncology | Hematology
Regional Cancer Care Associates LLC
92 2nd St, 
Hackensack, NJ 
Accepting New Patients
Offers Telehealth
Distinguished in Primary Lymphoma of the Brain
Regional Cancer Care Associates LLC
92 2nd St, 
Hackensack, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tatyana Feldman is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Feldman is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Feldman is currently accepting new patients.

Her clinical research consists of co-authoring 92 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NJ
Hospital Affiliations
Hackensack University Medical Center
Jfk University Medical Center
St Joseph's University Medical Center Inc
Languages Spoken
English
Russian
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

REGIONAL CANCER CARE ASSOCIATES LLC
92 2nd St, Hackensack, NJ 07601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Pembrolizumab, Vorinostat
Study Phase: Phase 1
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Pralatrexate
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2025
Intervention Type: Combination product
Study Drugs: VRx-3996, Valganciclovir
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Prednisone
Study Phase: Phase 2
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)
Enrollment Status: Terminated
Publish Date: September 23, 2024
Intervention Type: Drug
Study Drugs: ABT-199, Ibrutinib, Rituximab
Study Phase: Phase 1
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Enrollment Status: Terminated
Publish Date: March 13, 2019
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 17 Less Clinical Trials

92 Total Publications

Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results.
Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results.
Journal: Blood advances
Published: March 13, 2025
Similar Doctors
Distinguished in Primary Lymphoma of the Brain
Dr. Andrew D. Zelenetz
Oncology
Distinguished in Primary Lymphoma of the Brain
Dr. Andrew D. Zelenetz
Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (9.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Zelenetz is an Oncologist in New York, New York. Dr. Zelenetz is rated as an Elite provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Diffuse Large B-Cell Lymphoma (DLBCL).

Distinguished in Primary Lymphoma of the Brain
Dr. Michael L. Grossbard
Hematology Oncology | Hematology | Oncology
Distinguished in Primary Lymphoma of the Brain
Dr. Michael L. Grossbard
Hematology Oncology | Hematology | Oncology

New York University

560 1st Ave, 
New York, NY 
 (10.7 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances

Michael Grossbard is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Grossbard is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Hodgkin Lymphoma, Primary Lymphoma of the Brain, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

Distinguished in Primary Lymphoma of the Brain
Dr. Andre H. Goy
Oncology | Hematology
Distinguished in Primary Lymphoma of the Brain
Dr. Andre H. Goy
Oncology | Hematology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (0.1 miles away)
201-996-5900
Languages Spoken:
English, French, Italian, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Andre Goy is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Goy is rated as an Elite provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Tissue Biopsy. Dr. Goy is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feldman's expertise for a condition
ConditionClose
View All 12 Elite Conditions
View All 14 Distinguished Conditions
View All 15 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile